

Veronica Gil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11114648/publications.pdf>

Version: 2024-02-01

9
papers

719
citations

1163117
8
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

1509
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 659-667.	5.4	8
2	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	1.9	76
3	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
4	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.9	25
5	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. <i>Cell Reports</i> , 2019, 28, 2156-2168.e5.	6.4	129
6	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	7.0	111
7	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , 2018, 559, 363-369.	27.8	258
8	Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1824-1836.	4.1	65
9	Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 34087-34105.	1.8	26